Identification and characterization of the anti-SARS-CoV-2 activity of cationic amphiphilic steroidal compounds

References

• Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e244. DOI:10.1016/S1473-3099(20)30484-9.
   PubMed Web of Science ®Google Scholar
• Coronavirus (COVID-19) cases - statistics and research - our world in data. n.d. [cited 2021 Oct 20]. Available from: https://ourworldindata.org/covid-cases
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor. Cell. 2020;181(2):271–280.e8. DOI:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• V’-Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020;193(19):155–170. DOI:10.1038/s41579-020-00468-6
   Google Scholar
• Neufeldt CJ, Cortese M, Acosta EG, et al. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16(3):125–142. DOI:10.1038/nrmicro.2017.170.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. DOI:10.1038/s41577-021-00542-x.
   PubMed Web of Science ®Google Scholar
• Tang J. What can we learn about corticosteroid therapy as a treatment for COVID-19? Osteoporosis Int. n.d.;31(8):1595. DOI:10.5694/mja2.50577.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020;161(9):1–8. DOI:10.1210/endocr/bqaa127.
   Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Group, dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020;384:693–704. DOI:10.1056/NEJMOA2021436.
   PubMed Web of Science ®Google Scholar
• Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCov) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045. DOI:10.2807/1560-7917.ES.2020.25.3.2000045/CITE/PLAINTEXT.
   Web of Science ®Google Scholar
• Claro IM, Ramundo MS, Coletti TM, et al. Rapid viral metagenomics using SMART-9N amplification and nanopore sequencing. Wellcome Open Res. 2021:6241. 6. DOI:10.12688/wellcomeopenres.17170.1
   Google Scholar
• Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science. 2020;369(6508):1255–1260. DOI:10.1126/SCIENCE.ABD2161.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372. DOI:10.1126/SCIENCE.ABH2644.
   PubMed Web of Science ®Google Scholar
• Li H, Birol I. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094–3100. DOI:10.1093/BIOINFORMATICS/BTY191.
   PubMed Web of Science ®Google Scholar
• Li H, Handsaker B, Wysoker A, et al. The sequence alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–2079. DOI:10.1093/BIOINFORMATICS/BTP352.
   PubMed Web of Science ®Google Scholar
• Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability, mol. Biol Evol. 2013;30(4):772–780. DOI:10.1093/MOLBEV/MST010.
   PubMed Web of Science ®Google Scholar
• Kopylova E, Noé L, Touzet H SortMerna: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012;28(24):3211–3217. DOI:10.1093/BIOINFORMATICS/BTS611.
   PubMed Web of Science ®Google Scholar
• Kim D, Paggi JM, Park C, et al. Graph-Based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907–915. DOI:10.1038/s41587-019-0201-4.
   PubMed Web of Science ®Google Scholar
• Liao Y, Smyth GK, Shi W. The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47(8):e47–e47. DOI:10.1038/s41587-019-0201-4.
   PubMed Web of Science ®Google Scholar
• Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):1–12. DOI:10.1186/GB-2010-11-10-R106/COMMENTS.
   Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. DOI:10.1089/OMI.2011.0118.
   PubMed Web of Science ®Google Scholar
• Carol K, William B, Cuthill Innes C, et al. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160(7):1577–1579. DOI:10.1111/j.1476-5381.2010.00872.x.
   PubMed Web of Science ®Google Scholar
• Elliott L, Clare SS, Kendall DE, et al. ARRIVE 2.0 and the British. Br J Pharmacol. 2020;177(16):3611–3616. Journal of Pharmacology: Updated guidance for 2020. DOI:10.1111/bph.15178.
   PubMed Web of Science ®Google Scholar
• Nathalie Percie DS, Ahluwalia HV, Nathalie Percie DS, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18:1–6.
   Web of Science ®Google Scholar
• McCray PB, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. DOI:10.1128/JVI.02012-06.
   PubMed Web of Science ®Google Scholar
• Oladunni FS, Park JG, Pino PA, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;111(11):1–17. DOI:10.1038/s41467-020-19891-7.
   Google Scholar
• Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nat. 2020;583(7818):830–833. DOI:10.1038/s41586-020-2312-y.
   Google Scholar
• Salata C, Calistri A, Parolin C, et al. Antiviral activity of cationic amphiphilic drugs. 2017;15:483–492. DOI:10.1080/14787210.2017.1305888.
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell Res. 2020;30(3):269–271. DOI:10.1038/s41422-020-0282-0.
   PubMed Web of Science ®Google Scholar
• Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014;10(11):e1004502. DOI:10.1371/JOURNAL.PPAT.1004502.
   PubMed Web of Science ®Google Scholar
• Takano T, Endoh M, Fukatsu H, et al. The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antiviral Res. 2017;145:96–102. DOI:10.1016/j.antiviral.2017.07.022.
   PubMed Web of Science ®Google Scholar
• Khan N, Chen X, Geiger JD. Role of endolysosomes in severe acute respiratory syndrome coronavirus-2 infection and coronavirus disease 2019 pathogenesis: implications for potential treatments. Front Pharmacol. 2020;0:1739. DOI:10.3389/FPHAR.2020.595888.
   Google Scholar
• Tyler WH B, Cao Yiqun, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39. DOI:10.1093/NAR/GKR320.
   Web of Science ®Google Scholar
• Tummino TA, Rezelj VV, Fischer B, et al. Drug-Induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science 2021;373. DOI:10.1126/SCIENCE.ABI4708.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. DOI:10.1126/SCIENCE.ABI4708.
   PubMed Web of Science ®Google Scholar
• Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial, Eur. Respir J. 2020:2003725. DOI:10.1183/13993003.03725-2020.
   Google Scholar
• Consortium WST, Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. N Engl J Med. 2020;384(6):497–511. DOI:10.1056/NEJMOA2023184.
   PubMed Web of Science ®Google Scholar
• Zhao H, To KKW, Lam H, et al. Cross-Linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun. n.d.;12(1). DOI:10.1038/s41467-021-21825-w
   Web of Science ®Google Scholar
• Diosa-Toro M, Troost B, van de Pol D, et al. Tomatidine, a novel antiviral compound towards dengue virus. Antiviral Res. 2019;161:90–99. DOI:10.1016/J.ANTIVIRAL.2018.11.011.
   PubMed Web of Science ®Google Scholar
• Naciuk FF, Faria JDN, Eufrásio AG, et al. Development of selective steroid inhibitors for the glucose-6-phosphate dehydrogenase from Trypanosoma cruzi. ACS Med Chem Lett. 2020;11(6):1250–1256. DOI:10.1021/ACSMEDCHEMLETT.0C00106.
   PubMed Web of Science ®Google Scholar
• Romanutti C, Bruttomesso AC, Castilla V, et al. Anti-Adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives. Chemotherapy. 2010;56(2):158–165. DOI:10.1159/000313530.
   PubMed Web of Science ®Google Scholar
• Pedersen NC, North TW, Rigg R, et al. 16α-Bromo-Epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Immunol Immunopathol. 2003;94(3–4):133–148. DOI:10.1016/S0165-2427(03)00081-3.
   Google Scholar
• Reading, C., Dowding, C., Schramm, B., et al. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16α-bromoepiandrosterone (HE2000). Microbiol Infect. 2006;12(11):1082–1088. DOI:10.1111/J.1469-0691.2006.01520.X.
   Google Scholar
• Kornhuber J, Tripal P, Reichel M, et al. Functional Inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9–20. DOI:10.1159/000315101.
   PubMed Web of Science ®Google Scholar
• Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6(1):1–12. DOI:10.1021/ACSCHEMBIO.0C00875/SUPPL_FILE/CB0C00875_SI_001.PDF.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Mösbauer K, Hofmann-Winkler H, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nat. 2020;585:588–590. DOI:10.1038/s41392-021-00558-8.
   Google Scholar
• Mellott DM, Te Tseng C, Drelich A, et al. A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells. ACS Chem Biol. 2021;16(4):642–650. DOI:10.1038/s41586-020-2575-3.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Feldman R, Kodama E, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother. 1999;43(10):2479–2483. DOI:10.1128/AAC.43.10.2479.
   PubMed Web of Science ®Google Scholar